长春高新：会结合市场需求、产品价格变化等情况，合理安排发货等事宜

Group 1 - The core issue raised by investors is the reported shortage of Changchun High-tech's long-acting growth hormone after its inclusion in the medical insurance system [1] - Changchun High-tech responded by stating that it will manage the delivery of products based on market demand and price changes [1]